Hannong Chemicals Inc. 011500

KRX · South Korea · Consumer Non-Durables

KRW 14,550.00+160.00 (+1.11%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Hannong Chemicals Inc. 011500

KRX · South Korea · Consumer Non-Durables

KRW 14,550.00+160.00 (+1.11%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-31.69% · 6MFull-screen chart

Open KRW 14,400.00High KRW 14,590.00Low KRW 14,010.00Close KRW 14,550.00Volume 119.44K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 14,390.00
Day range: KRW 14,010.00 – KRW 14,590.00
52-week range: KRW 9,250.00 – KRW 29,450.00
Volume: 119.44K
Market cap: KRW 220.08B
P/E (TTM): 23.7
Dividend yield (annualized): 0.28%
Avg. volume (1Y): 362.09K

Performance

1 week

+8.66%

1 month

+2.90%

3 months

+6.36%

6 months

-29.71%

Year to date

+0.97%

1 year

+5.18%

Total return, dividends included.

Company profile

Sector: Consumer Non-Durables
Industry: Household/Personal Care
Country: South Korea
Exchange: KRX
Shares outstanding: 15.64M
Employees: 181
ISIN: KR7011500006
Beta: 0.94

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJul 01, 2026

Shoko Co., Ltd. Began Commercial Production of Pharmaceutical Excipient "Viscomedi" at Its South Korean Plant

TOKYO, July 01, 2026--Shoko Co., Ltd. (Head Office: Minato-ku, Tokyo; President & CEO: Kentaro Watanabe; hereinafter "Shoko"), a comprehensive commodity trading firm engaged in three business domains—chemicals, plastics, and metal & ceramics—is pleased to announce that, following the sales framework agreement announced in June 2025 with Hannong Chemicals Inc. (Anyang, Gyeonggi-do, South Korea; hereinafter "Hannong Chemicals"), the manufacturing plant for the new pharmaceutical excipient "Viscome

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.